Insider · CIK 0001055947
BVF PARTNERS L P/IL
Reports to the SEC for 77 companies · SAN FRANCISCO, CA
Transactions
50
Companies
77
Filings
7
CIK
0001055947
Forms 4 and 5
Insider transactions
| Date | Company | Value |
|---|---|---|
| 2026-09-16 | IMUXIMMUNIC, INC. · Stock OptionA Award | — |
| 2026-07-14 | XOMA Royalty CorpU Disposition from Tender | — |
| 2026-07-14 | XOMA Royalty CorpU Disposition from Tender | — |
| 2026-07-14 | XOMA Royalty CorpU Disposition from Tender | — |
| 2026-07-14 | XOMA Royalty CorpU Disposition from Tender | — |
| 2026-06-26 | KYMRKymera Therapeutics, Inc.S Sale | −$12.1M |
| 2026-06-26 | KYMRKymera Therapeutics, Inc.S Sale | −$66.8M |
| 2026-06-26 | KYMRKymera Therapeutics, Inc.S Sale | −$89.2M |
| 2026-06-26 | KYMRKymera Therapeutics, Inc.S Sale | −$5.52M |
| 2026-06-24 | KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2026-06-18 | OLMAOlema Pharmaceuticals, Inc. · Stock Option (Right to buy)A Award | — |
| 2026-06-17 | MLTXMoonLake Immunotherapeutics · Option to BuyA Award | — |
| 2026-05-14 | XOMA Royalty CorpSeries X Convertible Preferred StockC Conversion | — |
| 2026-05-14 | XOMA Royalty CorpC Conversion | +$1.66M |
| 2026-05-14 | XOMA Royalty CorpC Conversion | +$6.07M |
| 2026-05-14 | XOMA Royalty CorpC Conversion | +$9.32M |
| 2026-05-14 | XOMA Royalty CorpSeries X Convertible Preferred StockC Conversion | — |
| 2026-05-14 | XOMA Royalty CorpSeries X Convertible Preferred StockC Conversion | — |
| 2026-05-14 | XOMA Royalty CorpC Conversion | +$3.11M |
| 2026-05-14 | XOMA Royalty CorpSeries X Convertible Preferred StockC Conversion | — |
| 2026-03-31 | MLTXMoonLake ImmunotherapeuticsS Sale | −$32.4M |
| 2026-03-31 | MLTXMoonLake ImmunotherapeuticsS Sale | −$26.3M |
| 2026-03-31 | MLTXMoonLake ImmunotherapeuticsS Sale | −$4.17M |
| 2026-01-28 | RPTXRepare Therapeutics Inc.U Disposition from Tender | — |
| 2026-01-28 | RPTXRepare Therapeutics Inc.U Disposition from Tender | — |
| 2026-01-28 | RPTXRepare Therapeutics Inc.U Disposition from Tender | — |
| 2025-10-09 | EPIXESSA Pharma Inc.U Disposition from Tender | — |
| 2025-10-09 | EPIXESSA Pharma Inc.U Disposition from Tender | — |
| 2025-10-09 | EPIXESSA Pharma Inc.U Disposition from Tender | — |
| 2025-08-05 | EPIXESSA Pharma Inc.X Exercise of In-Money | +$20.334 |
| 2025-08-05 | EPIXESSA Pharma Inc.S Sale | −$148.354 |
| 2025-08-05 | EPIXESSA Pharma Inc.X Exercise of In-Money | +$148.163 |
| 2025-08-05 | EPIXESSA Pharma Inc. · Pre-funded WarrantsX Exercise of In-Money | — |
| 2025-08-05 | EPIXESSA Pharma Inc.S Sale | −$123.941 |
| 2025-08-05 | EPIXESSA Pharma Inc.S Sale | −$20.657 |
| 2025-08-05 | EPIXESSA Pharma Inc.X Exercise of In-Money | +$123.503 |
| 2025-08-05 | EPIXESSA Pharma Inc. · Pre-funded WarrantsX Exercise of In-Money | — |
| 2025-08-05 | EPIXESSA Pharma Inc. · Pre-funded WarrantsX Exercise of In-Money | — |
| 2025-06-30 | KYMRKymera Therapeutics, Inc.P Purchase | +$5.09M |
| 2025-06-30 | KYMRKymera Therapeutics, Inc.P Purchase | +$2.59M |
| 2025-06-30 | KYMRKymera Therapeutics, Inc.P Purchase | +$6.27M |
| 2025-06-25 | KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2025-06-13 | CBIOCRESCENT BIOPHARMA, INC. · Pre-Funded Warrants to Purchase Common StockJ Other | — |
| 2025-06-13 | CBIOCRESCENT BIOPHARMA, INC.J Other | — |
| 2025-06-13 | CBIOCRESCENT BIOPHARMA, INC.J Other | — |
| 2025-06-13 | CBIOCRESCENT BIOPHARMA, INC. · Pre-Funded Warrants to Purchase Common StockJ Other | — |
| 2025-06-13 | CBIOCRESCENT BIOPHARMA, INC.J Other | — |
| 2025-06-13 | CBIOCRESCENT BIOPHARMA, INC. · Pre-Funded Warrants to Purchase Common StockJ Other | — |
| 2025-06-11 | OLMAOlema Pharmaceuticals, Inc. · Stock Option (Right to buy)A Award | — |
| 2025-06-05 | MLTXMoonLake Immunotherapeutics · Option to BuyA Award | — |
Recent filings
- 4BIOTECHNOLOGY VALUE FUND L P0000921895-26-002590SEC(opens sec.gov)
- 4LAMPERT MARK N0000921895-26-001823SEC(opens sec.gov)
- 4BIOTECHNOLOGY VALUE FUND L P0000921895-26-001688SEC(opens sec.gov)
- 4BIOTECHNOLOGY VALUE FUND L P0000921895-26-001680SEC(opens sec.gov)
- 4BIOTECHNOLOGY VALUE FUND L P0000921895-26-001653SEC(opens sec.gov)
- 4BIOTECHNOLOGY VALUE FUND L P0000921895-26-001639SEC(opens sec.gov)
- 4LAMPERT MARK N0000921895-26-001435SEC(opens sec.gov)
Companies
- 4D Molecular Therapeutics, Inc.See Explanation of ResponsesFDMT
- ABBOTT BIOTHERAPEUTICS CORP10% Owner
- ADOLOR CORP10% Owner
- AEOLUS PHARMACEUTICALS, INC.10% Owner, Indirect Beneficial Owner
- AEROGEN INC10% Owner, Indirect Beneficial Owner
- Allakos Inc.10% Owner
- ALPINE IMMUNE SCIENCES, INC.10% Owner
- AMAG PHARMACEUTICALS, INC.10% Owner, Indirect Beneficial Owner
- ARENA PHARMACEUTICALS INC10% Owner, Indirect Beneficial Owner
- ARIAD PHARMACEUTICALS INCInsider
- ARQULE INC10% Owner
- ARRAY BIOPHARMA INCSee Explanation of Responses
- Astex Pharmaceuticals, Inc10% Owner
- ATHEROGENICS INC10% Owner
- AVADEL PHARMACEUTICALS PLC10% OwnerAVDL
- AVIGEN INC \DE10% Owner
- BIOCRYST PHARMACEUTICALS INC10% Owner, Indirect Beneficial OwnerBCRX
- Calithera Biosciences, Inc.10% Owner
- Capstone Holding Corp.See Explanation of ResponsesCAPS
- Cascadian Therapeutics, Inc.10% Owner
- Celera CORP10% Owner
- ChemoCentryx, Inc.See Explanation of Responses
- CONCERT PHARMACEUTICALS, INC.10% Owner
- CORVAS INTERNATIONAL INC10% Owner
- CRESCENT BIOPHARMA, INC.10% OwnerCBIO
- CTI BIOPHARMA CORPDirector, 10% Owner, See Remarks
- Cullinan Therapeutics, Inc.10% OwnerCGEM
- CURIS INC10% Owner, Indirect Beneficial OwnerCRIS
- CytoCore, Inc.10% Owner, Indirect Beneficial Owner
- CYTOKINETICS INCSee Explanaton of ResponsesCYTK
- CytomX Therapeutics, Inc.See Explanation of ResponsesCTMX
- DYNAVAX TECHNOLOGIES CORP10% OwnerDVAX
- Eledon Pharmaceuticals, Inc.10% OwnerELDN
- enGene Therapeutics Inc.10% OwnerENGN
- EPIRUS Biopharmaceuticals, Inc.10% Owner
- ESSA Pharma Inc.10% OwnerEPIX
- Euthymics Bioscience, Inc.10% Owner
- FIVE PRIME THERAPEUTICS, INC.10% Owner
- Foghorn Therapeutics Inc.10% OwnerFHTX
- GENAERA CORP10% Owner
- GYRE THERAPEUTICS, INC.See Explanation of ResponsesGYRE
- ICAGEN INC10% Owner
- IDEAYA Biosciences, Inc.See Explanation of ResponsesIDYA
- IMMUNE DESIGN CORP.10% Owner
- IMMUNIC, INC.Director, See Explanation of ResponsesIMUX
- INFINITY PHARMACEUTICALS, INC.See Explanation of Responses
- INHIBITEX, INC.10% Owner, Indirect Beneficial Owners
- INSMED Inc10% OwnerINSM
- KENT INTERNATIONAL HOLDINGS INCSee Explanation of Responses
- Kymera Therapeutics, Inc.Director, See Remarks and FootnotesKYMR
- LIGAND PHARMACEUTICALS INCSee Explanation of ResponsesLGND
- MEDICINOVA INC10% OwnerMNOV
- Merus N.V.10% OwnerMRUS
- MoonLake ImmunotherapeuticsDirector, 10% OwnerMLTX
- NEUROBIOLOGICAL TECHNOLOGIES INC /CA/10% Owner
- NEUROCRINE BIOSCIENCES INCSee Explanation of ResponsesNBIX
- NEUROGEN CORP10% Owner, Indirect Beneficial Owner
- Olema Pharmaceuticals, Inc.Director, See Explanation of ResponsesOLMA
- PALATIN TECHNOLOGIES INC10% OwnerPTN
- PALVELLA THERAPEUTICS, INC.See Explanation of ResponsesPVLA
- PHARMACOPEIA INC10% Owner, Indirect Beneficial Owners
- POINT Biopharma Global Inc.Former 10% Owner
- Principia Biopharma Inc.10% Owner
- Rain Oncology Inc.Director, See Remarks; Former 10% Owner
- Regulus Therapeutics Inc.10% Owner
- Repare Therapeutics Inc.10% OwnerRPTX
- REPLIGEN CORP10% Owner, Indirect Beneficial OwnerRGEN
- REPROS THERAPEUTICS INC.10% Owner, Indirect Beneficial Owner
- RIGEL PHARMACEUTICALS INC10% OwnerRIGL
- SGX PHARMACEUTICALS, INC.10% Owner, Indirect Beneficial Owner
- Structure Therapeutics Inc.10% OwnerGPCR
- Syndax Pharmaceuticals Inc10% OwnerSNDX
- Third Harmonic Bio, Inc.See Explanation of Responses
- Tobira Therapeutics, Inc.See Explanation of Responses
- Verastem, Inc.10% OwnerVSTM
- Xenon Pharmaceuticals Inc.10% OwnerXENE
- XOMA Royalty Corp10% Owner
Address
44 MONTGOMERY ST. 40TH FLOOR
SAN FRANCISCO, CA, 94104